This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
The antibody was designed and developed at Abzena’s Cambridge, UK,
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow
Subscribe To Our Newsletter & Stay Updated
